Emerging research suggest Retatrutide , a dual activator targeting both GLP-1 and GIP , could offer a promising development for weight loss . Preliminary clinical trials have demonstrated substantial https://getretatrutideaustralia.com/blog/retatrutide-vs-tirzepatide-semaglutide